The article by Bradford and Bradford is dedicated to ascertaining the extent of legal marijuana use in the United States in relation to other drugs after the subsequent law went into effect. The authors state that after the legalization, the number of prescriptions of spasticity- and glaucoma-related drugs decreased substantially (Bradford and Bradford, 1235). Ashley C. Bradford and W. David Bradford are credible researchers at the Department of Public Administration and Policy at the University of Georgia. I reference this article because it showcases the financial benefits of medical marijuana over other prescriptions.
Boehnke et al. wrote an article covering the efficacy of cannabis treatment. The author posits that the official status of marijuana as a Schedule I substance complicates the research into the effects of this drug on patients (Boehnke et al. 300). Although cannabis has been legalized, it is still seen in a primarily negative context. The authors represent three universities, which approved their research as a qualified source. I use this article since it clearly states that more studies are required to establish the efficiency of cannabis over other prescriptions.
The study by Reiman, Welty, and Solomon investigates marijuana’s capacity to relieve pain in comparison to opioid-based drugs. The researchers positively view the medical qualities of marijuana and prefer it to opioids (Reiman et al. 160). This article is published in a journal targeting specifically research into cannabis, thus making its author’s reliable researchers. My inclusion of this study in the list is justified by its focus on the benefits of marijuana over opioid medicine.
The research by Ishida et al. delves into the replacement of opioid prescriptions by marijuana in the United States. The authors exercise caution in shifting to cannabis, arguing that more studies are needed (Ishida et al. 6). All contributors to the article have experience in working with opioid medicine, which validates their concerns over suggested substitution. This article is useful to my research because it provides examples of patients who report better health conditions after supplanting opioids with cannabis.
Satterlund, Juliet, and Roland conducted research into the stigma surrounding the use of marijuana. They conclude that the drug’s reputation prevents patients from receiving cannabis treatment (10). The authors conduct regular studies on psychoactive drugs and provide insight into their inclusion in prescriptions. I decided to incorporate this source due to its justification for cannabis. Marijuana is presented as possessing natural value in contrast to alternative synthetic pills.
Works Cited
Boehnke, Kevin F., et al. “Qualifying Conditions of Medical Cannabis License Holders in the United States.” Health Affairs, vol. 38, no. 2, 2019, pp. 295-302.
Bradford, Ashley C., and Bradford David. W. “Medical Marijuana Laws Reduce Prescription Medication Use in Medicare Part D.” Health Affairs, vol. 35, no. 7, 2016, pp. 1230-1236.
Ishida, Julie H., et al. “Substitution of Marijuana for Opioids in a National Survey of US Adults.” PloS ONE, vol. 14, no. 10, 2019, pp. 1-8.
Reiman, Amanda, et al. “Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report.” Cannabis and Cannabinoid Research. vol. 2, no. 1, 2017, pp. 160-166.
Satterlund, Travis D., et al. “Stigma among California’s Medical Marijuana Patients.” Journal of Psychoactive Drugs, vol. 47, no. 1, 2015, pp. 10-17.